Receptos Inc (RCPT) 231.96 $RCPT
Relapsing Multiple Sclerosis (RMS) - Pipeline Review 2015
M2 - Wed Jan 06, 4:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/fmxb97/relapsing) has announced the addition of the "Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Multiple Sclerosis (RMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Multiple Sclerosis (RMS) and special features on late-stage and discontinued projects. The report features investigational drugs from across the globe covering over 20 therapy areas and nearly 3,000 indications. It enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope of the Report: - The report provides a snapshot of the global therapeutic landscape of Relapsing Multiple Sclerosis (RMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Multiple Sclerosis (RMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Multiple Sclerosis (RMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Multiple Sclerosis (RMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products. Companies Mentioned: - AbbVie Inc. - Actelion Ltd - BIOCAD - Cognosci, Inc. - F. Hoffmann-La Roche Ltd. - Genzyme Corporation - Merck KGaA - Pfenex Inc. - Receptos, Inc. - VivaCell Biotechnology Espana S.L. For more information visit http://www.researchandmarkets.com/research/fmxb97/relapsing
RCPT: 231.96 (-0.03), ABBV: 61.00 (+0.25), PFNX: 7.52 (+0.09)
Lori Kunkel, M.D., Joins Tocagen's Board of Directors
PR Newswire - Thu Sep 10, 7:00AM CDT
Tocagen Inc., a clinical-stage immuno-oncology company, today announced that Lori Kunkel, M.D., has joined the company's board of directors. Dr. Kunkel has more than twenty years of experience in oncology and immunology drug development and commercialization, including serving as chief medical officer at Pharmacyclics (acquired by AbbVie) and Proteolix, Inc. (acquired by Onyx Pharmaceuticals), which ultimately resulted in the global approvals of cancer therapeutics IMBRUVICA® and Kyprolis®, respectively.
RCPT: 231.96 (-0.03), CELGZ: 1.46 (-0.04)
Celgene Announces Expiration of Cash Tender Offer for Shares of Receptos, Inc.
BusinessWire - Tue Aug 25, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Receptos, Inc. at a price of $232.00 per share, net to the seller in cash, without interest and less required withholding taxes, expired at 12:00 midnight ET, at the end of the day on Monday, August 24, 2015.
RCPT: 231.96 (-0.03), CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Celgene's Deal-Making Magic Lifts Receptos 20% in July
Todd Campbell, The Motley Fool - Motley Fool - Wed Aug 12, 8:04AM CDT
After agreeing to be acquired by Celgene Corp , shares in Receptos soared higher by 19.9% in July, according to data from S&P Capital IQ . Celgene's $7.2 billion bid to acquire Receptos is slated to close on Aug. 24 and if it goes off...
RCPT: 231.96 (-0.03), CELG: 102.91 (-3.22)
Celgene wins Hart-Scott-Rodino Antitrust Clearance for Receptos acquisition
M2 - Wed Aug 12, 4:13AM CDT
Biopharmaceutical company Celgene (NasdaqGS:CELG) disclosed on Tuesday the expiry of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with respect to the tender offer for all issued and outstanding shares of common stock of Receptos (NasdaqGS:RCPT) on 10 August 2015.
RCPT: 231.96 (-0.03), CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Celgene Receives Antitrust Clearance for Receptos Acquisition
BusinessWire - Tue Aug 11, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR"
with respect to the previously announced tender offer by its wholly-owned subsidiary, Strix Corporation, for all issued and outstanding shares of common stock of Receptos, Inc. (NASDAQ:RCPT) at a price of $232.00 per share, net to the seller in cash, without interest and less required withholding taxes and subsequent merger of Strix Corporation with Receptos expired at 11:59 p.m. EDT on August 10, 2015. The expiration of the HSR waiting period satisfies one of the conditions to the closing of the pending acquisition, which remains subject to other customary closing conditions. Celgene expects the transaction to close in the third quarter of 2015.
RCPT: 231.96 (-0.03), CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Celgene Prices $8 Billion of Senior Unsecured Notes
BusinessWire - Tue Aug 04, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced the successful pricing of five series of senior unsecured notes for an aggregate principal amount of $8.0 billion. Of these notes, $1.0 billion will mature in 2018 and will bear interest at an annual rate of 2.125 percent, $1.5 billion will mature in 2020 and will bear interest at an annual rate of 2.875 percent, $1.0 billion will mature in 2022 and will bear interest at an annual rate of 3.550 percent, $2.5 billion will mature in 2025 and will bear interest at an annual rate of 3.875 percent and $2.0 billion will mature in 2045 and will bear interest at an annual rate of 5.000 percent. The 2.125 percent notes due 2018, the 2.875 percent notes due 2020, the 3.550 percent notes due in 2022, the 3.875 percent notes due in 2025 and the 5.000 percent notes due in 2045 were priced to yield 2.127 percent, 2.914 percent, 3.594 percent, 3.993 percent and 5.020 percent, respectively.
RCPT: 231.96 (-0.03), CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Celgene Announces Offering of Senior Unsecured Notes
BusinessWire - Mon Aug 03, 7:20AM CDT
Celgene Corporation (NASDAQ:CELG) today announced its intention to offer, subject to market and other conditions, senior unsecured notes under a shelf registration statement on Form S-3 on file with the Securities and Exchange Commission. The interest rate, the maturity dates and other key terms of the offering are to be determined at the time of pricing.
RCPT: 231.96 (-0.03), CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Celgene begins tender offer for Receptos at USD232.00 per share
M2 - Wed Jul 29, 5:05AM CDT
Pharmaceutical company Celgene (NasdaqGS:CELG) disclosed on Tuesday that it has commenced its tender offer for all outstanding shares of common stock of Receptos (NasdaqGS:RCPT) at a price of USD232.00 per share, net to the seller in cash, without interest and less required withholding taxes.
RCPT: 231.96 (-0.03), CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Celgene Corporation Commences Tender Offer for Receptos, Inc.
BusinessWire - Tue Jul 28, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that its direct wholly-owned subsidiary, Strix Corporation, has commenced its previously announced tender offer for all outstanding shares of common stock of Receptos, Inc. (NASDAQ: RCPT) at a price of $232.00 per share, net to the seller in cash, without interest and less required withholding taxes. The tender offer is being made in connection with the Agreement and Plan of Merger, dated July 14, 2015, by and among Celgene, Strix Corporation and Receptos, Inc.
RCPT: 231.96 (-0.03), CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Celgene Rolling Along (but You Already Knew That)
Brian Orelli, The Motley Fool - Motley Fool - Thu Jul 23, 1:47PM CDT
The big picture numbers when Celgene released second quarter earnings Thursday weren't surprising since the company pre-released its revenue and earnings when it announced the acquisition of Receptos last week. But the details of where the...
RCPT: 231.96 (-0.03), ABBV: 61.00 (+0.25), CELG: 102.91 (-3.22)
Celgene Q2 Earnings & Revenues In Line, Keeps View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 12:26PM CDT
Celgene Corporation (CELG) reported second-quarter 2015 earnings of $1.08 per share (including stock-based compensation expenses and tax adjustments), in line with the Zacks Consensus Estimate.
RCPT: 231.96 (-0.03), JUNO: 42.98 (-2.55), AMAG: 21.04 (-0.82), CELG: 102.91 (-3.22)
Stull, Stull & Brody Launches Investigation Into Possible Breaches of Fiduciary Duty by the Board of Directors of Receptos, Inc.
GlobeNewswire - Wed Jul 22, 6:02PM CDT
Stull, Stull & Brody (www.ssbny.com) announces that a class action has been filed and that it is investigating potential claims on behalf of shareholders of Receptos, Inc. (NASDAQ:RCPT) ("Receptos" or the "Company" concerning whether the Company's Board of Directors breached its fiduciary duty by entering into an agreement and plan of merger under which all of the Company's outstanding shares will be acquired by Celgene Corporation for $232.00 per share in cash.
RCPT: 231.96 (-0.03), CELGZ: 1.46 (-0.04)
Morgan & Morgan Announces That a Shareholder Class Action Has Been Filed on Behalf of Receptos, Inc. Shareholders -- RCPT
GlobeNewswire - Wed Jul 22, 3:36PM CDT
Morgan & Morgan announces that a shareholder class action has been filed in the Delaware Court of Chancery against the Board of Directors of Receptos, Inc. ("Receptos" or "the Company" (Nasdaq:RCPT) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Celgene Corporation ("Celgene" .
RCPT: 231.96 (-0.03), CELGZ: 1.46 (-0.04)
Results of the Phase 2 TOUCHSTONE Trial - Report on Receptos, Inc.
PR Newswire - Wed Jul 22, 8:20AM CDT
ACI Association has initiated research coverage on Receptos, Inc. (NASDAQ: RCPT). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
RCPT: 231.96 (-0.03)
Celgene Buys Receptos. Is Arena Pharmaceuticals Next?
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 21, 3:27PM CDT
Arena Pharmaceuticals (NASDAQ: ARNA) jumped more than 6% last Wednesday. But it had nothing to do with the biotech's only approved drug, obesity treatment Belviq. It wasn't even anything Arena Pharmaceuticals did. Instead, it appears the bump...
BIIB: 246.13 (-4.33), RCPT: 231.96 (-0.03), ARNA: 1.99 (-0.07), NVS: 78.94 (-1.57), CELG: 102.91 (-3.22)
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Receptos, Inc. And Encourages Investors To Contact The Firm For Additional Information
BusinessWire - Mon Jul 20, 1:22PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Receptos, Inc. ("Receptos" or the "Company" (NasdaqGS: RCPT) relating to the proposed buyout of the Company by Celgene Corporation.
RCPT: 231.96 (-0.03)
Is Celgene Brilliant or Downright Crazy?
Todd Campbell, The Motley Fool - Motley Fool - Sun Jul 19, 12:17PM CDT
Source: Flickr user DonkeyHotey. Celgene is on a spending spree that is reshaping its future, but investors are right to question whether or not the company's decision to fork over more than $8 billion in the past month is savvy or crazy....
RCPT: 231.96 (-0.03), JUNO: 42.98 (-2.55), CELG: 102.91 (-3.22)
EQUITY ALERT: The Rosen Law Firm Announces Investigation of Receptos, Inc. Concerning its Proposed Sale to Celgene Corporation
BusinessWire - Fri Jul 17, 5:52PM CDT
The Rosen Law Firm, a global investor rights law firm, announces that it is investigating the Board of Directors of Receptos, Inc. (NASDAQ: RCPT) for possible breaches of fiduciary duty and other violations of law by failing to adequately shop Receptos to maximize shareholder value before agreeing to be acquired by Celgene Corporation (NASDAQ: CELG).
RCPT: 231.96 (-0.03), CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Receptos, Inc. Acquisition By Celgene Corporation May Not Be In The Best Interest Of RCPT Shareholders
PR Newswire - Fri Jul 17, 10:29AM CDT
The fairness of the proposed acquisition of Receptos, Inc. ("RCPT" or the "Company" by Celgene Corporation ("Celgene" is the subject of an investigation by WeissLaw LLP, a national class action, shareholder rights law firm. The investigation is focusing on possible breaches of fiduciary duty and other violations of law by the Board of Directors of RCPT for agreeing to sell the Company to Celgene. On July 14, 2015, the Company announced it had reached a definitive agreement for Celgene to acquire RCPT in a transaction valued at approximately $7.2 billion. Under the terms of the agreement, RCPT shareholders will receive $232.00 in cash for each RCPT share they own.
RCPT: 231.96 (-0.03), CELGZ: 1.46 (-0.04)
Relapsing Multiple Sclerosis (RMS) - Pipeline Review 2015
M2 - Wed Jan 06, 4:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/fmxb97/relapsing) has announced the addition of the "Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Multiple Sclerosis (RMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Multiple Sclerosis (RMS) and special features on late-stage and discontinued projects. The report features investigational drugs from across the globe covering over 20 therapy areas and nearly 3,000 indications. It enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope of the Report: - The report provides a snapshot of the global therapeutic landscape of Relapsing Multiple Sclerosis (RMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Multiple Sclerosis (RMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Multiple Sclerosis (RMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Multiple Sclerosis (RMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products. Companies Mentioned: - AbbVie Inc. - Actelion Ltd - BIOCAD - Cognosci, Inc. - F. Hoffmann-La Roche Ltd. - Genzyme Corporation - Merck KGaA - Pfenex Inc. - Receptos, Inc. - VivaCell Biotechnology Espana S.L. For more information visit http://www.researchandmarkets.com/research/fmxb97/relapsing
RCPT: 231.96 (-0.03), ABBV: 61.00 (+0.25), PFNX: 7.52 (+0.09)
Lori Kunkel, M.D., Joins Tocagen's Board of Directors
PR Newswire - Thu Sep 10, 7:00AM CDT
Tocagen Inc., a clinical-stage immuno-oncology company, today announced that Lori Kunkel, M.D., has joined the company's board of directors. Dr. Kunkel has more than twenty years of experience in oncology and immunology drug development and commercialization, including serving as chief medical officer at Pharmacyclics (acquired by AbbVie) and Proteolix, Inc. (acquired by Onyx Pharmaceuticals), which ultimately resulted in the global approvals of cancer therapeutics IMBRUVICA® and Kyprolis®, respectively.
RCPT: 231.96 (-0.03), CELGZ: 1.46 (-0.04)
Celgene Announces Expiration of Cash Tender Offer for Shares of Receptos, Inc.
BusinessWire - Tue Aug 25, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Receptos, Inc. at a price of $232.00 per share, net to the seller in cash, without interest and less required withholding taxes, expired at 12:00 midnight ET, at the end of the day on Monday, August 24, 2015.
RCPT: 231.96 (-0.03), CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Celgene's Deal-Making Magic Lifts Receptos 20% in July
Todd Campbell, The Motley Fool - Motley Fool - Wed Aug 12, 8:04AM CDT
After agreeing to be acquired by Celgene Corp , shares in Receptos soared higher by 19.9% in July, according to data from S&P Capital IQ . Celgene's $7.2 billion bid to acquire Receptos is slated to close on Aug. 24 and if it goes off...
RCPT: 231.96 (-0.03), CELG: 102.91 (-3.22)
Celgene wins Hart-Scott-Rodino Antitrust Clearance for Receptos acquisition
M2 - Wed Aug 12, 4:13AM CDT
Biopharmaceutical company Celgene (NasdaqGS:CELG) disclosed on Tuesday the expiry of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with respect to the tender offer for all issued and outstanding shares of common stock of Receptos (NasdaqGS:RCPT) on 10 August 2015.
RCPT: 231.96 (-0.03), CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Celgene Receives Antitrust Clearance for Receptos Acquisition
BusinessWire - Tue Aug 11, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR"
with respect to the previously announced tender offer by its wholly-owned subsidiary, Strix Corporation, for all issued and outstanding shares of common stock of Receptos, Inc. (NASDAQ:RCPT) at a price of $232.00 per share, net to the seller in cash, without interest and less required withholding taxes and subsequent merger of Strix Corporation with Receptos expired at 11:59 p.m. EDT on August 10, 2015. The expiration of the HSR waiting period satisfies one of the conditions to the closing of the pending acquisition, which remains subject to other customary closing conditions. Celgene expects the transaction to close in the third quarter of 2015. RCPT: 231.96 (-0.03), CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Celgene Prices $8 Billion of Senior Unsecured Notes
BusinessWire - Tue Aug 04, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced the successful pricing of five series of senior unsecured notes for an aggregate principal amount of $8.0 billion. Of these notes, $1.0 billion will mature in 2018 and will bear interest at an annual rate of 2.125 percent, $1.5 billion will mature in 2020 and will bear interest at an annual rate of 2.875 percent, $1.0 billion will mature in 2022 and will bear interest at an annual rate of 3.550 percent, $2.5 billion will mature in 2025 and will bear interest at an annual rate of 3.875 percent and $2.0 billion will mature in 2045 and will bear interest at an annual rate of 5.000 percent. The 2.125 percent notes due 2018, the 2.875 percent notes due 2020, the 3.550 percent notes due in 2022, the 3.875 percent notes due in 2025 and the 5.000 percent notes due in 2045 were priced to yield 2.127 percent, 2.914 percent, 3.594 percent, 3.993 percent and 5.020 percent, respectively.
RCPT: 231.96 (-0.03), CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Celgene Announces Offering of Senior Unsecured Notes
BusinessWire - Mon Aug 03, 7:20AM CDT
Celgene Corporation (NASDAQ:CELG) today announced its intention to offer, subject to market and other conditions, senior unsecured notes under a shelf registration statement on Form S-3 on file with the Securities and Exchange Commission. The interest rate, the maturity dates and other key terms of the offering are to be determined at the time of pricing.
RCPT: 231.96 (-0.03), CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Celgene begins tender offer for Receptos at USD232.00 per share
M2 - Wed Jul 29, 5:05AM CDT
Pharmaceutical company Celgene (NasdaqGS:CELG) disclosed on Tuesday that it has commenced its tender offer for all outstanding shares of common stock of Receptos (NasdaqGS:RCPT) at a price of USD232.00 per share, net to the seller in cash, without interest and less required withholding taxes.
RCPT: 231.96 (-0.03), CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Celgene Corporation Commences Tender Offer for Receptos, Inc.
BusinessWire - Tue Jul 28, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that its direct wholly-owned subsidiary, Strix Corporation, has commenced its previously announced tender offer for all outstanding shares of common stock of Receptos, Inc. (NASDAQ: RCPT) at a price of $232.00 per share, net to the seller in cash, without interest and less required withholding taxes. The tender offer is being made in connection with the Agreement and Plan of Merger, dated July 14, 2015, by and among Celgene, Strix Corporation and Receptos, Inc.
RCPT: 231.96 (-0.03), CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Celgene Rolling Along (but You Already Knew That)
Brian Orelli, The Motley Fool - Motley Fool - Thu Jul 23, 1:47PM CDT
The big picture numbers when Celgene released second quarter earnings Thursday weren't surprising since the company pre-released its revenue and earnings when it announced the acquisition of Receptos last week. But the details of where the...
RCPT: 231.96 (-0.03), ABBV: 61.00 (+0.25), CELG: 102.91 (-3.22)
Celgene Q2 Earnings & Revenues In Line, Keeps View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 12:26PM CDT
Celgene Corporation (CELG) reported second-quarter 2015 earnings of $1.08 per share (including stock-based compensation expenses and tax adjustments), in line with the Zacks Consensus Estimate.
RCPT: 231.96 (-0.03), JUNO: 42.98 (-2.55), AMAG: 21.04 (-0.82), CELG: 102.91 (-3.22)
Stull, Stull & Brody Launches Investigation Into Possible Breaches of Fiduciary Duty by the Board of Directors of Receptos, Inc.
GlobeNewswire - Wed Jul 22, 6:02PM CDT
Stull, Stull & Brody (www.ssbny.com) announces that a class action has been filed and that it is investigating potential claims on behalf of shareholders of Receptos, Inc. (NASDAQ:RCPT) ("Receptos" or the "Company"
concerning whether the Company's Board of Directors breached its fiduciary duty by entering into an agreement and plan of merger under which all of the Company's outstanding shares will be acquired by Celgene Corporation for $232.00 per share in cash. RCPT: 231.96 (-0.03), CELGZ: 1.46 (-0.04)
Morgan & Morgan Announces That a Shareholder Class Action Has Been Filed on Behalf of Receptos, Inc. Shareholders -- RCPT
GlobeNewswire - Wed Jul 22, 3:36PM CDT
Morgan & Morgan announces that a shareholder class action has been filed in the Delaware Court of Chancery against the Board of Directors of Receptos, Inc. ("Receptos" or "the Company"
(Nasdaq:RCPT) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Celgene Corporation ("Celgene" . RCPT: 231.96 (-0.03), CELGZ: 1.46 (-0.04)
Results of the Phase 2 TOUCHSTONE Trial - Report on Receptos, Inc.
PR Newswire - Wed Jul 22, 8:20AM CDT
ACI Association has initiated research coverage on Receptos, Inc. (NASDAQ: RCPT). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
RCPT: 231.96 (-0.03)
Celgene Buys Receptos. Is Arena Pharmaceuticals Next?
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 21, 3:27PM CDT
Arena Pharmaceuticals (NASDAQ: ARNA) jumped more than 6% last Wednesday. But it had nothing to do with the biotech's only approved drug, obesity treatment Belviq. It wasn't even anything Arena Pharmaceuticals did. Instead, it appears the bump...
BIIB: 246.13 (-4.33), RCPT: 231.96 (-0.03), ARNA: 1.99 (-0.07), NVS: 78.94 (-1.57), CELG: 102.91 (-3.22)
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Receptos, Inc. And Encourages Investors To Contact The Firm For Additional Information
BusinessWire - Mon Jul 20, 1:22PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Receptos, Inc. ("Receptos" or the "Company"
(NasdaqGS: RCPT) relating to the proposed buyout of the Company by Celgene Corporation. RCPT: 231.96 (-0.03)
Is Celgene Brilliant or Downright Crazy?
Todd Campbell, The Motley Fool - Motley Fool - Sun Jul 19, 12:17PM CDT
Source: Flickr user DonkeyHotey. Celgene is on a spending spree that is reshaping its future, but investors are right to question whether or not the company's decision to fork over more than $8 billion in the past month is savvy or crazy....
RCPT: 231.96 (-0.03), JUNO: 42.98 (-2.55), CELG: 102.91 (-3.22)
EQUITY ALERT: The Rosen Law Firm Announces Investigation of Receptos, Inc. Concerning its Proposed Sale to Celgene Corporation
BusinessWire - Fri Jul 17, 5:52PM CDT
The Rosen Law Firm, a global investor rights law firm, announces that it is investigating the Board of Directors of Receptos, Inc. (NASDAQ: RCPT) for possible breaches of fiduciary duty and other violations of law by failing to adequately shop Receptos to maximize shareholder value before agreeing to be acquired by Celgene Corporation (NASDAQ: CELG).
RCPT: 231.96 (-0.03), CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Receptos, Inc. Acquisition By Celgene Corporation May Not Be In The Best Interest Of RCPT Shareholders
PR Newswire - Fri Jul 17, 10:29AM CDT
The fairness of the proposed acquisition of Receptos, Inc. ("RCPT" or the "Company"
by Celgene Corporation ("Celgene" is the subject of an investigation by WeissLaw LLP, a national class action, shareholder rights law firm. The investigation is focusing on possible breaches of fiduciary duty and other violations of law by the Board of Directors of RCPT for agreeing to sell the Company to Celgene. On July 14, 2015, the Company announced it had reached a definitive agreement for Celgene to acquire RCPT in a transaction valued at approximately $7.2 billion. Under the terms of the agreement, RCPT shareholders will receive $232.00 in cash for each RCPT share they own. RCPT: 231.96 (-0.03), CELGZ: 1.46 (-0.04)
